Related Experiment Video

Updated: Jul 31, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

[Hemodynamic effects of intravenously administered celiprolol in patient with coronary heart disease and depressed

F Leisch, W Herbinger

    Arzneimittel-Forschung
    |April 1, 1987
    PubMed

    Insights

    Celiprolol, a beta-1 blocker with intrinsic sympathomimetic activity, significantly reduced arterial and pulmonary pressures in patients with coronary heart disease. However, intravenous celiprolol may precipitate pump failure in severely compromised left ventricular function.

    Area of Science:

    • Cardiology
    • Pharmacology

    Context:

    • Investigated hemodynamic effects of celiprolol in patients with coronary heart disease and impaired left ventricular function.
    • Included 15 patients with ejection fraction <60% and elevated left ventricular end-diastolic pressure (LVEDP).

    Purpose:

    • To evaluate the hemodynamic profile of intravenous celiprolol in patients with compromised cardiac function.
    • To assess the impact of celiprolol on heart rate, arterial pressure, pulmonary pressure, cardiac output, and peripheral resistance.

    Summary:

    • Intravenous celiprolol (10 mg) significantly reduced arterial pressure (p<0.01), LVEDP (p<0.001), and pulmonary pressure (p<0.01) without altering heart rate or significantly changing cardiac output and total peripheral resistance.
    • Celiprolol demonstrated properties of a beta-1 receptor blocker with strong intrinsic sympathomimetic activity and vasodilating effects, even on preload.
    • One patient with severe left ventricular failure and pulmonary edema could not be evaluated, and intravenous celiprolol administration in severely depressed left ventricular function carries a risk of pump failure.

    Impact:

    • Provides insights into the hemodynamic effects of celiprolol in a specific patient population.
    • Highlights potential risks associated with celiprolol use in patients with severely compromised left ventricular function.
    • Contributes to understanding the pharmacological profile of celiprolol, particularly its vasodilating and ISA properties.

    More Related Videos

    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

    Published on: January 21, 2018

    Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

    Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

    Published on: May 28, 2019

    Related Concept Videos

    Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Imaging Studies for Cardiovascular System I:Echocardiography01:17

    Imaging Studies for Cardiovascular System I:Echocardiography

    Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
    Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion, evaluates...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...